Sponsor Directory

Bristol-Myers Squibb clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

2038

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions: Navlimetostat, mFOLFIRINOX Treatment Regimen; Drug
Lead sponsor: Daniel Nussbaum, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hodgkin Lymphoma
Interventions: Ruxolitinib, Nivolumab; Drug
Lead sponsor: Veronika Bachanova; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 6
States / cities: Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 3 more

Conditions: Alzheimer Disease, Early Onset
Interventions: BMS-986446, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 119
States / cities: Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 78 more

Conditions: Urothelial Cancer
Interventions: Nivolumab, Ipilimumab, Gemcitabine, Cisplatin, Carboplatin; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 29
States / cities: Anchorage, Alaska • Fresno, California • Santa Rosa, California + 24 more

Conditions: Castration-resistant Prostate Cancer, Metastatic Cancer
Interventions: Cabozantinib, Nivolumab; Drug
Lead sponsor: Rana McKay, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: La Jolla, California • Chicago, Illinois • Dallas, Texas + 1 more

Conditions: Myeloma, Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Elotuzumab, Iberdomide, Dexamethasone; Drug
Lead sponsor: Omar Nadeem, MD; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Breast Neoplasms
Interventions: Pumitamig, Nab-paclitaxel/Paclitaxel, Gemcitabine, Carboplatin, Eribulin, Matching placebo; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 71
States / cities: Springdale, Arkansas • La Jolla, California • Los Alamitos, California + 56 more

Conditions: Schizophrenia
Interventions: Xanomeline/Trospium Chloride, Placebo; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 472 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 32
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 27 more

Conditions: Pulmonary Fibrosis
Interventions: BMS-986278; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Not listed
Enrollment: 2,380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Birmingham, Alabama • Ocala, Florida • Philadelphia, Pennsylvania

Conditions: Diffuse Midline Glioma, Diffuse Midline High-grade Glioma, Medulloblastoma, Ependymoma
Interventions: PEP-CMV vaccine, Tetanus booster, Nivolumab, Temozolomide; Biological · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 4 Years to 25 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2051
U.S. locations: 3
States / cities: St Louis, Missouri • Durham, North Carolina • Houston, Texas

Conditions: Relapsed or Refractory Multiple Myeloma (RRMM)
Interventions: BMS-986393, Cyclophosphamide, Fludarabine, Daratumumab, Pomalidomide, Dexamethasone, Carfilzomib; Drug
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Eligibility: 18 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 21
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more

Conditions: Hepatocellular Carcinoma
Interventions: Nivolumab, Relatlimab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 2
States / cities: Baltimore, Maryland • Columbus, Ohio

About this Bristol-Myers Squibb sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where Bristol-Myers Squibb is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Bristol-Myers Squibb trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Bristol-Myers Squibb clinical trials

Filter and sort this sponsor

Live official records

A Study of Perioperative Navlimetostat Combined With Modified FOLFIRINOX in Patients With MTAP-Deleted Pancreatic Cancer

Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease

Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer

Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer

ELEVATE-MM: Elotuzumab, Iberdomide and Dexamethasone Post Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma

About this Bristol-Myers Squibb sponsor directory page